New York – September 30, 2026 -- Direct-to-patient healthcare company Ro presented the first real-world evidence on Novo Nordisk's oral Wegovy pill at the EASD2026 meeting in Milan on September 30, based on outcomes from patients on its platform who switched from an injectable GLP-1.